F ungal pathogens are notoriously difficult to treat because of antifungal drug toxicity and drug resistance, and the limited armamentarium (1). Some drug classes inhibit fungal growth but do not efficiently eliminate pathogens, and there is a pressing need for advances in antifungal therapy. The problem is especially acute in the immunocompromised. In a recent issue of PNAS, Cowen et al. (2) d...
